Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Therachon Moves 'Academic Prototype' Towards Clinic

Executive Summary

Emerging Company Profile: Switzerland-based Therachon is developing therapeutics for rare genetic pediatric diseases with a lead program in achondroplasia, also known as genetic dwarfism. CEO Luca Santarelli explains the mechanism behind lead molecule TA-46 and plans moving forward.

You may also be interested in...



Mitsubishi’s Oral Radicava Provides Convenience Option For ALS

Oral or feeding tube administration of the cerebral neuroprotectant should offer flexible dosing options for amyotrophic lateral sclerosis patients, the firm says.

Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter

Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.

FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump

Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel